期刊文献+

血清CK19、CA125、高迁移率蛋白a1在宫颈癌患者中的表达及意义

原文传递
导出
摘要 目的探讨血清细胞角蛋白19(CK19)、糖类抗原125(CA125)、高迁移率蛋白a1在宫颈癌患者中的表达及意义。方法选取2018年5月至2019年7月本院收治的宫颈癌患者140例为宫颈癌组,宫颈上皮内瘤变患者80例为癌前病变组,健康女性60例为对照组。采集各组清晨空腹肘静脉血3 ml,检测血清CK19、CA125、高迁移率蛋白a1水平。结果宫颈癌组患者血清CK19(161.53±18.25)pg/ml、CA125(50.73±9.58)U/ml、高迁移率蛋白a1(178.91±26.36)ng/ml,明显高于癌前病变组和对照组,癌前病变组明显高于对照组,差异均有统计学意义(均P<0.01)。血清CK19、CA125、高迁移率蛋白a1水平在不同临床分期、分化程度、淋巴结转移情况的宫颈癌患者间比较差异均有统计学意义(均P<0.05)。结论宫颈癌患者血清CK19、CA125、高迁移率蛋白a1高表达,与临床分期、分化程度、淋巴结转移情况密切相关。
作者 郭静 齐卫红
出处 《中国卫生工程学》 CAS 2021年第4期672-673,676,共3页 Chinese Journal of Public Health Engineering
  • 相关文献

参考文献8

二级参考文献85

  • 1Atlanta. American Cancer Society Cancer Facts & Figures [J ]. USA:American Cancer Society, 2012, 20(2) :307 - 320.
  • 2Badgwell D, Bast RC, Early detection of ovarian cancer[ J ]. Dis- ease Markers, 2007, 23(5 - 6) :397 - 410.
  • 3McIntosh MW, Dreacher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovar- ian carcinoma[J] .Gynecologic Oncology, 2004, 95(1):9- 15.
  • 4Comamala M, Pinard M, Th6riault C, et al. Downregulation of cell surface CA125 / MUC16 induces epithelial - to - mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells[ J ]. British Journal of Cancer, 2011,104 ( 6 ) : 989-999.
  • 5Ueland FR, Desimone CP, Seamon LG, eta/. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors[J]. Obstetrics and Gynecology, 2011, 117 (6): 1 289 - 1 297.
  • 6Kirchhoff C, Habben I, Ivell R, et al. A major human epi - didymis - specific cDNA encodes a protein with sequence homology to ex- traeellular proteinase inhibitors [J ]. Biol Reprod, 1991, 45 ( 2 ) : 350 - 357.
  • 7Schummer M, Ng WV, Bumgarner RE, et al. Comparative hy- br/d/zation o[ an array 0[21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas [ J ]. Gene, 1999, 238 (2) :375- 385.
  • 8Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the di- agnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstetrics and Gynecology, 2011, 118(2) :280 - 288.
  • 9Escudero JM, Auge JM, Comparison of serum human epididyrnis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases[J ]. Clinical Chemistry, 2011,57(11):1 534-1 544.
  • 10Chang X, Ye X, Dong L, et al. Human epididymis protein 4 (HE4) as a serum tumor blomarker in patients with ovarian[J]. Carcino- ma. International Journal of Gynecological Cancer, 2011, 21 ( 5 ) : 852 - 858.

共引文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部